Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
AIClouDr

ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
FinanceJunshi Biosciences

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms

Becton Dickinson Considers Spinning Off Life Sciences Division
Becton Dickinson and Company

Becton Dickinson Considers Spinning Off Life Sciences Division

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition
BaxterCarlyle

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition

Show More